Indication
Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Medicine details

Medicine name:
dolutegravir lamivudine (Dovato)
SMC ID:
SMC2205
Pharmaceutical company
GlaxoSmithKline UK Ltd
BNF chapter
Submission type
Abbreviated
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019